CordenPharma has agreed to acquire AmbioPharm, a US-headquartered peptide API CDMO with facilities in North Augusta, South Carolina and Shanghai, China. The transaction adds approximately 400 employees and strengthens CordenPharma's peptide manufacturing network across the United States, Europe, and Asia.
Source: PharmaDeviceNews
The deal gives CordenPharma a second US peptide facility through the North Augusta site, which focuses on purification and lyophilization of peptide APIs, complementing its existing Colorado operations. The Shanghai campus adds upstream capacity across solid-phase peptide synthesis, liquid-phase peptide synthesis, and hybrid synthesis.
This acquisition comes as peptide therapeutics gain momentum across metabolic disease, oncology, and endocrinology. CDMOs with deep peptide experience are being pushed to scale both capacity and technical capability to meet growing demand from drug developers working with longer, more complex peptide APIs.